Cargando…
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Novel agents addressing non-amyloid, non-tau targets in Alzheimer’s Disease (AD) comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most of the target processes identified in the Common Alzheimer’s Disease Research Ontology (CADRO) are represented by novel agent...
Autores principales: | Cummings, Jeffrey L., Osse, Amanda M. Leisgang, Kinney, Jefferson W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582128/ https://www.ncbi.nlm.nih.gov/pubmed/37728864 http://dx.doi.org/10.1007/s40265-023-01938-w |
Ejemplares similares
-
Inflammation as a central mechanism in Alzheimer's disease
por: Kinney, Jefferson W., et al.
Publicado: (2018) -
Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease
por: Yang, Zhengshi, et al.
Publicado: (2023) -
Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation
por: Cummings, Jeffrey, et al.
Publicado: (2022) -
Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease
por: Cummings, Jeffrey, et al.
Publicado: (2022) -
The “rights” of precision drug development for Alzheimer’s disease
por: Cummings, Jeffrey, et al.
Publicado: (2019)